Monday - July 27, 2026
Imfinzi Plus Imjudo Combined With Lenvatinib and TACE Reduced the Risk of Disease Progression or Death by 30% in Embolization-Eligible Unresectable Liver Cancer in EMERALD-3 Phase III Trial
June 02, 2026
WILMINGTON, Delaware, June 2 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

IMFINZI(R) (durvalumab) plus IMJUDO(R) (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial

Positive overall survival trend in favor of STRIDE regimen with lenvatinib and TACE

-

Posit . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products